CN107286166B - Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives - Google Patents
Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives Download PDFInfo
- Publication number
- CN107286166B CN107286166B CN201610220316.0A CN201610220316A CN107286166B CN 107286166 B CN107286166 B CN 107286166B CN 201610220316 A CN201610220316 A CN 201610220316A CN 107286166 B CN107286166 B CN 107286166B
- Authority
- CN
- China
- Prior art keywords
- tetrahydro
- pyrrolo
- benzazepin
- fluoro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AGPZUEDYVLUKMF-UHFFFAOYSA-N 1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Chemical class O=C1NCCC2=CNC3=CC=CC1=C23 AGPZUEDYVLUKMF-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims abstract description 27
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims abstract description 27
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 claims abstract description 17
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- -1 methoxy, ethoxy, n-propyl Propoxy, isopropoxy Chemical group 0.000 claims description 92
- 150000001875 compounds Chemical class 0.000 claims description 77
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Chemical class 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract description 13
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract description 13
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 3
- XJBGDSOYCGILCD-UHFFFAOYSA-N 1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indole Chemical class C1NCCC2=CNC3=CC=CC1=C23 XJBGDSOYCGILCD-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 68
- 230000015572 biosynthetic process Effects 0.000 description 41
- 238000003786 synthesis reaction Methods 0.000 description 41
- 239000007787 solid Substances 0.000 description 37
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- 239000012467 final product Substances 0.000 description 33
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
- 150000003852 triazoles Chemical class 0.000 description 14
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108091007743 BRCA1/2 Proteins 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- KNTCUVWNFYUDDX-UHFFFAOYSA-N 4-(6-fluoro-9-oxo-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-2-yl)benzoic acid Chemical compound FC=1C=C2C=3C(=C(NC=3C=1)C1=CC=C(C(=O)O)C=C1)CCNC2=O KNTCUVWNFYUDDX-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VREMSFQRWXHFSG-UHFFFAOYSA-N 4-[2-(4,5-dimethyl-1,3-thiazol-2-yl)-5-[3-(hydroxymethoxy)phenyl]-1H-tetrazol-3-yl]benzenesulfonic acid Chemical compound CC=1N=C(SC=1C)N1N(NC(=N1)C1=CC(=CC=C1)OCO)C1=CC=C(C=C1)S(=O)(=O)O VREMSFQRWXHFSG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940125941 PARP1/2 inhibitor Drugs 0.000 description 2
- 108091026813 Poly(ADPribose) Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SHLWOAANDCXUKI-UHFFFAOYSA-N (2-methoxy-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C(OC)=C1 SHLWOAANDCXUKI-UHFFFAOYSA-N 0.000 description 1
- DJOMWLVGTUQULT-UHFFFAOYSA-N (3-chloro-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1Cl DJOMWLVGTUQULT-UHFFFAOYSA-N 0.000 description 1
- OFUYEZFEGZXILY-UHFFFAOYSA-N (3-methoxy-5-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC(OC)=CC(B(O)O)=C1 OFUYEZFEGZXILY-UHFFFAOYSA-N 0.000 description 1
- GQBWFAIHGHHNMM-UHFFFAOYSA-N (4-fluoro-3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC(B(O)O)=CC=C1F GQBWFAIHGHHNMM-UHFFFAOYSA-N 0.000 description 1
- LXGMDDVQLGJPIT-UHFFFAOYSA-N (4-methoxy-3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC(B(O)O)=CC=C1OC LXGMDDVQLGJPIT-UHFFFAOYSA-N 0.000 description 1
- JAVZEYJXDZSLOV-UHFFFAOYSA-N (4-methoxycarbonyl-3-methylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1C JAVZEYJXDZSLOV-UHFFFAOYSA-N 0.000 description 1
- PQCXFUXRTRESBD-UHFFFAOYSA-N (4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1 PQCXFUXRTRESBD-UHFFFAOYSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical class C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- CYNXYQWCYHOAOY-UHFFFAOYSA-N 1-(furan-2-yl)piperazine Chemical class C1CNCCN1C1=CC=CO1 CYNXYQWCYHOAOY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- OCUSYBHPZIFMRI-UHFFFAOYSA-N 1-benzazepin-6-one Chemical compound N1=CC=CC=C2C(=O)C=CC=C21 OCUSYBHPZIFMRI-UHFFFAOYSA-N 0.000 description 1
- ZJYMYRYATOYCIF-UHFFFAOYSA-N 1-cycloheptylsulfonylpiperazine Chemical compound C1(CCCCCC1)S(=O)(=O)N1CCNCC1 ZJYMYRYATOYCIF-UHFFFAOYSA-N 0.000 description 1
- QLEIDMAURCRVCX-UHFFFAOYSA-N 1-propylpiperazine Chemical compound CCCN1CCNCC1 QLEIDMAURCRVCX-UHFFFAOYSA-N 0.000 description 1
- ANGVDUJFWRWPCE-UHFFFAOYSA-N 1-thiophen-2-ylpiperazine Chemical class C1CNCCN1C1=CC=CS1 ANGVDUJFWRWPCE-UHFFFAOYSA-N 0.000 description 1
- JEVLAMZYGHEJIS-UHFFFAOYSA-N 1-thiophen-2-ylsulfonylpiperazine Chemical compound C=1C=CSC=1S(=O)(=O)N1CCNCC1 JEVLAMZYGHEJIS-UHFFFAOYSA-N 0.000 description 1
- XJSUUJDMFDMIGK-UHFFFAOYSA-N 3,5-dimethylpiperidin-4-amine Chemical compound CC1CNCC(C)C1N XJSUUJDMFDMIGK-UHFFFAOYSA-N 0.000 description 1
- RDRQUUWCJTYHCT-UHFFFAOYSA-N 4-(trifluoromethyl)piperidine Chemical compound FC(F)(F)C1CCNCC1 RDRQUUWCJTYHCT-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 238000011460 HER2-targeted therapy Methods 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- FKHMNODTEFBVPC-UHFFFAOYSA-N cyclobutyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCC1 FKHMNODTEFBVPC-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZSZROXCAFYZNHE-UHFFFAOYSA-N cyclohexyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCCCC1 ZSZROXCAFYZNHE-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- KIALFUYSJAAJSU-UHFFFAOYSA-N cyclopropyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CC1 KIALFUYSJAAJSU-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- SADPINFEWFPMEA-UHFFFAOYSA-N furan-2-yl(piperazin-1-yl)methanone Chemical compound C=1C=COC=1C(=O)N1CCNCC1 SADPINFEWFPMEA-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- DIUAWEVAOAYVBP-UHFFFAOYSA-N molport-035-773-933 Chemical compound O=C1NCCC2=C(Br)NC3=CC(F)=CC1=C32 DIUAWEVAOAYVBP-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- VUNXBQRNMNVUMV-UHFFFAOYSA-N phenyl(piperazin-1-yl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCNCC1 VUNXBQRNMNVUMV-UHFFFAOYSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IULDWWUGMGLWOB-UHFFFAOYSA-N piperazin-1-yl(pyridin-2-yl)methanone Chemical compound C=1C=CC=NC=1C(=O)N1CCNCC1 IULDWWUGMGLWOB-UHFFFAOYSA-N 0.000 description 1
- YLYAETTZHAUHNX-UHFFFAOYSA-N piperazin-1-yl(pyridin-4-yl)methanone Chemical compound C=1C=NC=CC=1C(=O)N1CCNCC1 YLYAETTZHAUHNX-UHFFFAOYSA-N 0.000 description 1
- KUKGMDPEGDZCTL-UHFFFAOYSA-N piperazin-1-yl(thiophen-2-yl)methanone Chemical compound C=1C=CSC=1C(=O)N1CCNCC1 KUKGMDPEGDZCTL-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical class OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- FSDNTQSJGHSJBG-UHFFFAOYSA-N piperidine-4-carbonitrile Chemical class N#CC1CCNCC1 FSDNTQSJGHSJBG-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- 229950004707 rucaparib Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一类取代1，3，4，5‑四氢‑6H‑吡咯并[4，3，2‑EF][2]苯并氮杂‑6‑酮衍生物、及其作为治疗上有效的多聚(ADP‑核糖)聚合酶(PARP)抑制剂的应用。具体的，本发明涉及一种通式(I)所示的新的取代1，3，4，5‑四氢‑6H‑吡咯并[4，3，2‑EF][2]苯并氮杂‑6‑酮类衍生物、及其药物组合物，作为选择性PARP‑1/2抑制剂在预防或治疗与PARP‑1/2相关疾病中的用途。 The present invention relates to a class of substituted 1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-EF][2]benzazepine-6-one derivatives and their therapeutically effective of poly(ADP-ribose) polymerase (PARP) inhibitors. Specifically, the present invention relates to a new substituted 1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-EF][2]benzazepine represented by the general formula (I). Use of -6-ketone derivatives, and pharmaceutical compositions thereof, as selective PARP-1/2 inhibitors in the prevention or treatment of PARP-1/2-related diseases.
Description
Technical Field
The present invention relates to substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-ones and their use as therapeutically effective poly (ADP-ribose) polymerase (PARP) inhibitors.
Background
PARP is a short name for poly (ADP-ribose) polymerase, a ribozyme closely related to single-stranded DNA damage repair, and plays a key role in repairing DNA damage and maintaining genome integrity. PARP is a large family, including 18 subtypes (Ame, j.c., c.spenhauer, and g.de murcia.bioessays 26: 882-93). Among PARP, only PARP-1 and PARP-2 are involved in the repair of single-strand breaks in D NA. Among them, PARP-1 is most abundant in eukaryotic cells, and the functional study thereof is also most intensive. PARP-1 mediated DNA repair plays a multiple molecular biological role: on one hand, PARP can repair DNA damage caused by oxidation or chemotherapeutic drugs and is an important factor causing chemotherapy or radiotherapy drug resistance; on the other hand, according to synthetic lethality theory, if synthetic lethality exists between two genes, Cell survival is not affected when either gene is inhibited or mutated alone, but inhibition of both genes simultaneously results in apoptosis (Kraus W.L.and Lis, J.T. (2003). Cell 113: 677-683; Ame, J.C., C.Spenlehuer, and G.de Murcia.Bioessays 26: 882-93.).
PARP-1/2 is recruited to the site of DNA damage and is activated following DNA binding by its zinc finger, and then poly (ADP-ribose) on histone glutamate residues. This generates highly negatively charged ADP-ribose chains, which in turn lead to unwinding and repair of damaged DNA by base excision repair mechanisms. PARP-1 is responsible for most of the DNA damage (> 90%) associated with PARP activity. Due to its multifunctional role, activation of PARP-1/2 has played a role in a variety of human diseases, such as cancer, stroke, myocardial infarction, inflammation, hypertension, atherosclerosis, and diabetes.
Radiation and chemotherapy are two important therapeutic approaches for cancer treatment. Ionizing radiation and DNA-methylating agents kill cancer cells by mechanisms involving the breaking of single strands of DNA. However, single strand breaks activate PARP-1 and initiate base excision repair mechanisms to repair the damage, resulting in reduced efficacy or development of drug resistance. When PARP-1 activity is inhibited, single-stranded DNA becomes persistent, which leads to genomic abnormalities and apoptosis, ultimately leading to cell death (Dantzer, f., g.de La Rubia, et al.biochemistry 2000; 39: 7559-69). Thus, PARP-1 inhibitors may be used as adjunctive anti-Cancer agents to potentiate the clinical effects of radiation and chemotherapy (Plummer R, Jones C, et al. Clin Cancer Res.2008Dec 1; 14 (23): 7917-23).
Breast and ovarian cancer are the major diseases causing death in women. Mutations BRCA1 or BRCA2 account for 3-5% of all breast cancers in breast cancer and up to 5% or more in ovarian cancer (R.Wooster and B.L.Weber (2003). N.Engl.J.Med.348 (23): 2339-2347). Triple negative breast cancer refers to breast cancer that lacks both estrogen and progestin receptors and does not express HER2, representing approximately 15% of all breast cancers, and which is unresponsive to current estrogen therapy and HER2 targeted therapies and has no standard treatment regimen. BRCA1/2 plays an essential role in the repair of DNA double strand breaks by a mechanism known as homologous recombination. BRCA1/2 gene-deficient cells are unable to repair DNA double strand breaks, but rely primarily on PARP-1/2-mediated base excision repair to maintain genetic integrity. Inhibition of PARP-1 activity results in synthetic lethality in BRCA1/2 gene-deficient cancer cells (Bryant, H.E., N.Schultz, H.D.Thomas, et al (2005). Nature.434: 913-917). Thus, PARP-1/2 inhibitors can be engineered as single agents for cancer treatment through defective DNA repair.
Currently, there are several selective PARP-1/2 inhibitors currently in clinical stage (e.g. AZD2281, ABT-888, and AG014699, etc.). Clinical evaluation of these drugs includes breast cancer, ovarian cancer, prostate cancer, colorectal cancer, pancreatic cancer, liver cancer, melanoma, gastric cancer, solid tumors, and the like.
In conclusion, PARP-1/2 inhibitor is not only a sensitizer for chemotherapy and radiotherapy, but also has inhibitory effect on the gene mutation (BRCA1/2 mutation) or HR defect tumor when used alone.
Disclosure of Invention
The invention aims to provide a novel substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-ketone compound, a derivative thereof or a pharmaceutically acceptable salt thereof.
The invention also aims to provide application of the compound serving as a novel high-selectivity PARP-1/2 inhibitor in preparing medicines for preventing or treating PARP enzyme-related diseases, wherein the PARP enzyme-related diseases comprise cancers (such as breast cancer, ovarian cancer, prostate cancer, colorectal cancer, pancreatic cancer, liver cancer, melanoma, gastric cancer, solid tumors and the like), various ischemic diseases and neurodegenerative diseases (such as Parkinson's disease, Alzheimer's disease and the like).
In order to achieve the above objects, the present invention provides substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-ones represented by the following general formula I:
wherein:
R1，R2，R3，R4，R5，R6each represents hydrogen and C1-C3Alkyl of (C)1-C3Alkoxy, halogen, trifluoromethyl or cyano of (a);
R7，R8one of them is-COA;
R7，R8the other represents hydrogen, C1-C3Alkyl of (C)1-C3Alkoxy, halogen, trifluoromethyl, cyano of (a);
a is one of the following groups:
R9represents hydrogen, methyl, halogen, hydroxyl, cyano, amino, trifluoromethyl;
n is 0, 1, 2;
R10represents hydrogen, methyl, halogen, hydroxyl, cyano, trifluoromethyl;
x and Y respectively represent C, N;
R11represents hydrogen, C1-C3Alkyl, phenyl, R1Substituted phenyl, C5-C6Heteroaryl, acyl, sulfonyl of (a);
wherein acyl is-C (═ O) R12，R12Is an acyl substituent, said substituent being C1-C3Alkyl radical, C3-C7Cycloalkyl, phenyl, R1Substituted phenyl, C5-C6An aromatic hetero group of (a);
wherein sulfonyl is-S (═ O)2R12，R12Is an acyl substituent, said substituent being C1-C3Alkyl radical, C3-C7Cycloalkyl, phenyl, R1Substituted phenyl, C5-C6The heteroaryl of (1).
The present invention also provides pharmaceutical compositions comprising at least one pharmaceutically acceptable carrier, and at least one compound of formula (I) and pharmaceutically acceptable salts thereof as described herein for use as PARP inhibitors.
As described in this application "C1-C3The "alkyl group" of (a) means a methyl group, an ethyl group, an n-propyl group or an isopropyl group; said "C1-C3The "alkoxy group" of (a) means a methoxy group, an ethoxy group, a n-propoxy group, an isopropoxy group; the halogen refers to F, Cl, Br and I; said "C3-C7Cycloalkyl "means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl; said "C5-C6By heteroaryl is meant a 5 to 6 membered aromatic monocyclic ring comprising 1-3 heteroatoms selected from N, O, S, the remaining ring atoms being carbon.
Typical compounds of the present invention include, but are not limited to, the following compounds of table 1:
or a pharmaceutically acceptable salt thereof.
Examples of pharmaceutically acceptable salts include inorganic and organic salts, such as hydrochloride, hydrobromide, sulfate, phosphate, citrate, tartrate, succinate, maleate, fumarate, tonsil and oxalate salts.
Part of the compounds of the invention can be prepared by the following general synthesis method:
starting materials I1And I2(orI5) Preparing an intermediate I by Suzuki coupling reaction3(or I)6) Intermediates I3(or I)6) Hydrolyzing to obtain acid intermediate I4(or I)7) The acid intermediate is condensed with an amine (A) to produce the final product I.
Wherein the raw material I1Pro.res AT org, according to AT Gillmore, M Badland et al.&Prepared according to the procedure reported in dev.2012, pp 1897.
The invention relates to substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepine-6-one derivatives which are PARP-1/2 inhibitors, and the compounds can be used for treating various clinical diseases, such as cancers, caused by abnormal activity of PARP-1/2. Such diseases include, but are not limited to, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, liver cancer, melanoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, lung cancer, gastric cancer, pancreatic cancer.
Meanwhile, the invention also comprises the application of the compound in treating other diseases caused by abnormal PARP-1/2 activity, such as central nervous system diseases such as apoplexy and neurodegenerative diseases.
The derivative can be formed into a composition for treating related cancers and other diseases by oral administration, injection and the like in the process of treating diseases.
The composition comprises a therapeutically effective amount of the above compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The mentioned carriers refer to the carriers conventional in the pharmaceutical field, such as: diluents, excipients such as water, etc.; binders such as cellulose derivatives, gelatin, polyvinylpyrrolidone, etc.; fillers such as starch and the like; disintegrating agents such as calcium carbonate, sodium bicarbonate; in addition, other adjuvants such as flavoring agents and sweeteners may also be added to the composition.
For oral administration, it can be prepared into conventional solid preparations such as tablet, powder or capsule; for injection, it can be prepared into injection.
The various dosage forms of the composition of the present invention can be prepared by conventional methods in the medical field, wherein the content of the active ingredient is 0.1-99.5% (by weight).
The administration amount of the present invention may vary depending on the route of administration, age, body weight of the patient, type and severity of the disease to be treated, etc., and the daily dose thereof is 0.005 to 30mg/kg body weight (oral administration) or 0.005 to 30mg/kg body weight (injection).
Examples
The present invention is further illustrated below with reference to specific examples, which are not intended to limit the scope of the invention.
Example 1
The compound (I-1) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4- (4- (cyclopropanoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Step 1: 2-bromo-8-fluoro-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (400mg, 1.41mmol), 4-methoxycarbonylphenylboronic acid (305mg, 1.69mmol), Pd (dppf) Cl2(103mg, 0.14mmol) and sodium carbonate (300mg, 2.83mmol) were added DMF (8mL)/H2In O (2mL), N2Heating to 80-90 ℃ under protection and reacting for 3 h. The reaction solution was cooled to room temperature and H was added2O (20mL) and dichloromethane (30mL), drying and concentrating to dryness to obtain 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-methoxycarbonylphenyl) -6H-pyrrolo [4,3,2-EF][2]The crude benzazepin-6-one was used for the next reaction.
Step 2: step 1 product tetrahydrofuran (10mL)/H was added2To a solution of O (5mL), sodium hydroxide (282mg, 7.05mmol) was added and the mixture was heated to 70 ℃ for reaction for 3 hours. Cooling the reaction solution to room temperature, adjusting pH to 2 with 1N dilute hydrochloric acid, stirring for 30min, filtering, and vacuum drying to obtain 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (0.33g, two-step yield 73.3%), MS (m/z): 325[ M + H ]]+。
And step 3: 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (100mg, 0.31mmol), benzotriazol-N, N' -tetramethyluronium hexafluorophosphate (HBTU, 129mg, 0.34mmol), 1-cyclopropylformylpiperazine (52mg, 0.34mmol), N-diisopropylethylamine (DIPEA,80mg, 0.62mmol), DMF (3mL) was added to the reaction flask and stirred at room temperature for 2 h. Dropwise addition of H2O (5mL), stirring, solid precipitation, filtration to give a grey solid, recrystallization from methanol (10mL) to give 8-fluoro-1, 3,4, 5-tetrahydro-2- (4- (4- (cyclopropanoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-1), white solid (70mg, yield 49.3%). MS (m/z): 461[ M + Na ]]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.12-7.97(m，5H)，7.76(s，1H)，7.32(s，1H)，3.75-3.42(m，10H)，2.72-2.69(m，2H)，1.26-1.21(m，1H)，0.73-0.70(m，4H)。
Example 2
The compound (I-2) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4- (4-hydroxypiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
The synthesis of compound I-2 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 4-hydroxypiperidines. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4- (4-hydroxypiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-2), white solid. MS (m/z): 430[ M + Na ]]+。1HNMR(DMSO-d6)：δ：11.39(br，1H)，8.11-7.97(m，5H)，7.77(s，1H)，7.32(s，1H)，4.29(br，1H)，3.72-3.38(m，7H)，2.70-2.66(m，2H)，1.86-1.67(m，4H)。
Example 3
The compound (I-3) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-pyridinyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-3 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-8-fluoro-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 3-methoxycarbonyl-4-fluorobenzeneboronic acid) and (2-pyridyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-pyridyl) piperazine-1-carbonyl) Phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-3), white solid. MS (m/z): 488[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.59(s，1H)，8.39(m，1H)，8.01-7.87(m，3H)，7.52-7.35(m，3H)，6.72-6.66(m，2H)，3.89-3.81(m，4H)，3.60-3.50(m，6H)，2.73-2.69(t，J＝5.6Hz，2H)。
Example 4
The compound (I-4) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (3-methyl-5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [4, 3-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-4 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 3-methyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [4, 3-A ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (3-methyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [4, 3-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-4), white solid. MS (m/z): 463[ M + H]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.58(s，1H)，8.40(m，1H)，8.02-7.89(m，2H)，7.48-7.39(m，2H)，4.46(s，2H)，4.32-4.25(m，2H)，3.68-3.54(m，4H)，2.73-2.69(t，J＝5.6Hz，2H)，2.45(s，3H)。
Example 5
The compound (I-5) 8-fluoro-1, 3,4, 5-tetrahydro-2- (3-methyl-4- (4-methylpiperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-5 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (3-methyl-4-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-8-fluoro-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 4-methoxycarbonyl-3-methylbenzeneboronic acid) and 1-methylpiperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (3-methyl-4- (4-methylpiperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-5), white solid. MS (m/z): 421[ M + H]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.01-7.97(m，3H)，7.79-7.77(m，2H)，7.32(s，1H)，3.49-3.45(m，6H)，2.70-2.66(m，2H)，2.47(s，3H)，2.32-2.25(m，7H)。
Example 6
The compound (I-6) 8-cyano-9-methyl-1, 3,4, 5-tetrahydro-2- (5-methoxy-3- (4-trifluoromethylpiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-6 was carried out as in example 1 starting from 8-cyano-9-methyl-1, 3,4, 5-tetrahydro-2- (5-methoxy-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-8-cyano-9-methyl-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 3-methoxycarbonyl-5-methoxyphenylboronic acid) and 4-trifluoromethylpiperidine. To obtain a final product 8-cyano-9-methyl-1, 3,4, 5-tetrahydro-2- (5-methoxy-3- (4-trifluoromethylpiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-6), white solid. MS (m/z): 511[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.19-8.17(m，2H)，8.01(br，1H)，7.62(s，1H)，6.39(s，1H)，3.85(s，3H)，3.47-3.42(m，6H)，2.73-2.69(t，J＝5.6Hz，2H)，2.34-2.31(m，4H)，1.69-1.55(m，4H)。
Example 7
The compound (I-7)7, 9-dimethoxy-1, 3,4, 5-tetrahydro-2- (4-trifluoromethyl-3- (3-methylpiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
The synthesis of compound I-7 was carried out as in example 1 starting from 7, 9-dimethoxy-1, 3,4, 5-tetrahydro-2- (4-trifluoromethyl-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-7, 9-dimethoxy-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 3-methoxycarbonyl-4-trifluoromethylphenylboronic acid) and 4-methylpiperidine. Obtaining the final product7, 9-dimethoxy-1, 3,4, 5-tetrahydro-2- (4-trifluoromethyl-3- (3-methylpiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-7), white solid. MS (m/z): 516[ M + H]+。1H NMR(DMSO-d6)：δ：11.37(br，1H)，8.54(s，1H)，8.01-7.98(m，2H)，7.86-7.84(m，1H)，6.58(s，1H)，3.85(s，6H)，3.49-3.43(m，6H)，2.75-2.71(m，2H)，1.69-1.45(m，5H)，0.95-0.93(d，J＝8.0Hz，3H)。
Example 8
The compound (I-8) 8-chloro-1, 3,4, 5-tetrahydro-2- (2, 4, 6-trimethyl-3- (4-phenylpiperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-8 was carried out as in example 1 starting from 8-chloro-1, 3,4, 5-tetrahydro-2- (2, 4, 6-trimethyl-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-8-chloro-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 3-methoxycarbonyl-2, 4, 6-trimethylbenzeneboronic acid) and 1-phenylpiperazine. To obtain the final product 8-chloro-1, 3,4, 5-tetrahydro-2- (2, 4, 6-trimethyl-3- (4-phenylpiperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-8), white solid. MS (m/z): 528[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.03-8.01(m，2H)，7.68(s，1H)，7.25-7.19(m，3H)，6.90-6.82(m，3H)，3.52-3.43(m，10H)，2.75-2.73(m，2H)，2.45(s，3H)，2.42(s，3H)，2.38(s，3H)。
Example 9
The compound (I-9) 8-fluoro-1, 3,4, 5-tetrahydro-2- (2-methoxy-4- (4- (2-pyridinyloxy) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-9 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (2-methoxy-4-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-8-fluoro-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzo (b) isAza-6-one and 4-methoxycarbonyl-2-methoxyphenylboronic acid) and (2-pyridinoyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (2-methoxy-4- (4- (2-pyridine acyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-9), white solid. MS (m/z): 528[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.72(m，1H)，8.36(m，1H)，8.02-7.88(m，4H)，7.66(m，2H)，7.32(s，1H)，3.82(s，3H)，3.60-3.49(m，10H)，2.70-2.66(m，2H)。
Example 10
The compound (I-10) 8-isopropoxy-1, 3,4, 5-tetrahydro-2- (3-chloro-4- (4- (cyclobutanoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-10 was carried out as in example 1 starting from 8-isopropoxy-1, 3,4, 5-tetrahydro-2- (3-chloro-4-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-8-isopropoxy-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 4-methoxycarbonyl-3-chlorobenzeneboronic acid) and 1-cyclobutylformylpiperazine. To obtain the final product 8-isopropoxy-1, 3,4, 5-tetrahydro-2- (3-chloro-4- (4- (cyclobutyryl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepine-6- (I-10), white solid. MS (m/z): 550[ M + H ]]+。1HNMR(DMSO-d6)：δ：11.38(br，1H)，8.19(s，1H)，8.36(m，1H)，8.03-7.88(m，3H)，7.58(s，1H)，7.15(s，1H)，4.85(m，1H)，3.63-3.49(m，10H)，2.88-2.75(m，3H)，2.31-2.15(m，6H)，1.35(s，6H)。
Example 11
The compound (I-11) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (3-trifluoromethyl-5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [4, 3-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-11 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 3-trifluoromethyl-5, 6,7, 8-tetrahydro [1, 2, 4]]Triazole [4, 3-A ]]A pyrazine. To obtain a final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (3-trifluoromethyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [4, 3-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-11), white solid. MS (m/z): 517[ M + H]+。1HNMR(DMSO-d6)：δ：11.39(br，1H)，8.59(s，1H)，8.41(m，1H)，8.01-7.89(m，2H)，7.47-7.39(m，2H)，4.47(s，2H)，4.31-4.27(m，2H)，3.66-3.54(m，4H)，2.72-2.69(t，J＝5.6Hz，2H)。
Example 12
The compound (I-12) 8-trifluoromethyl-1, 3,4, 5-tetrahydro-2- (4-bromo-3- (3-cyano-5, 6, 7, 8-tetrahydroimidazo [1, 5-a ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-12 was carried out as in example 1 starting from 8-trifluoromethyl-1, 3,4, 5-tetrahydro-2- (4-bromo-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 3-cyano-5, 6, 7, 8-tetrahydroimidazo [1, 5-a ]]A pyrazine. To obtain a final product 8-trifluoromethyl-1, 3,4, 5-tetrahydro-2- (4-bromo-3- (3-cyano-5, 6, 7, 8-tetrahydroimidazo [1, 5-a ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-12), white solid. MS (m/z): 584[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.49(s，1H)，8.25(s，1H)，8.02-7.89(m，3H)，7.58(s，1H)，7.43(s，1H)，4.38-4.35(m，4H)，3.62-3.59(m，4H)，3.66-3.54(m，4H)，2.73-2.69(t，J＝5.6Hz，2H)。
Example 13
The compound (I-13) 8-isopropyl-1, 3,4, 5-tetrahydro-2- (4-cyano-3- (6-chloro-1, 2, 3, 4-tetrahydropyrrolo [1, 2-a ] pyrazine-2-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-13 was carried out as in example 1 starting from 8-isopropyl-1, 3,4, 5-tetrahydro-2- (4-cyano-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 6-chloro-1, 2, 3, 4-tetrahydropyrrolo [1, 2-a ]]A pyrazine. To obtain the final product 8-isoPropyl-1, 3,4, 5-tetrahydro-2- (4-cyano-3- (6-chloro-1, 2, 3, 4-tetrahydropyrrolo [1, 2-a)]Pyrazine-2-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-13), white solid. MS (m/z): 513[ M + H]+。1H NMR(DMSO-d6)：δ：11.37(br，1H)，8.78(s，1H)，8.22(m，1H)，7.99-7.89(m，3H)，7.26(s，1H)，6.05-6.03(d，J＝8.0Hz，1H)，5.73-5.71(d，J＝8.0Hz，1H)，4.48-4.42(m，4H)，3.64-3.59(m，4H)，2.87-2.75(m，3H)，1.29(s，6H)。
Example 14
The compound (I-14)1, 3,4, 5-tetrahydro-2- (4-methoxy-3- (4-amino-3, 5-dimethylpiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-14 was carried out as in example 1 starting from 1,3,4, 5-tetrahydro-2- (4-methoxy-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (synthesis analogous to example 1, starting from 2-bromo-1, 3,4, 5-tetrahydro-6H-pyrrolo [4,3, 2-EF)][2]Benzazepin-6-one and 3-methoxycarbonyl-4-methoxyphenylboronic acid) and 4-amino-3, 5-dimethylpiperidine. To obtain the final product 1,3,4, 5-tetrahydro-2- (4-methoxyl-3- (4-amino-3, 5-dimethylpiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-14), white solid. MS (m/z): 511[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.49(s，1H)，8.01(br，1H)，7.81-7.69(m，3H)，7.27-7.24(m，2H)，5.09(br，2H)，3.85(s，3H)，3.47-3.42(m，6H)，2.73-2.69(m，3H)，1.92(m，2H)，0.95(m，6H)。
Example 15
The compound (I-15) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-isopropoxy-3- (4-cyanopiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-15 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-isopropoxy-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 4-cyanopiperidines. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-iso)Propoxy-3- (4-cyanopiperidine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-15), white solid. MS (m/z): 475[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.37(br，1H)，8.49(s，1H)，8.02(br，1H)，7.80-7.77(m，2H)，7.33-7.27(m，2H)，4.69-4.65(m，1H)，3.47-3.41(m，6H)，2.71-2.62(m，3H)，2.35-2.31(m，4H)，1.29(s，6H)。
Example 16
The compound (I-16) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [4, 3-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-16 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [4, 3-A ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [4, 3-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-16), white solid. MS (m/z): 449[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.58(s，1H)，8.41-8.39(m，2H)，8.01-7.90(m，2H)，7.47-7.39(m，2H)，4.45(s，2H)，4.31-4.28(m，2H)，3.66-3.54(m，4H)，2.71-2.69(m，2H)。
Example 17
The compound (I-17) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-17 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and piperazines. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-17), white solid. MS (m/z): 410[ M + H]+。1H NMR(DMSO-d6)：δ：11.37(br，1H)，8.58(s，1H)，8.40(m，1H)，8.01-7.87(m，2H)，7.48-7.33(m，2H)，3.48-3.46(m，6H)，2.83-2.75(m，6H)，1.92(br，1H)。
Example 18
The compound (I-18) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (cycloheptylsulfonyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-18 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one and 1- (cycloheptylsulfonyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (cycloheptylsulfonyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-18), white solid. MS (m/z): 571[ M + H]+。1H NMR(DMSO-d6)：δ：11.37(br，1H)，8.58(s，1H)，8.39(m，1H)，8.01-7.89(m，2H)，7.48-7.35(m，2H)，3.48-3.46(m，6H)，2.93-2.77(m，7H)，2.03-1.67(m，12H)。
Example 19
The compound (I-19) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (cyclohexanoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-19 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 1- (cyclohexanoyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (cyclohexanoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-19), white solid. MS (m/z): 521[ M + H]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.57(s，1H)，8.41(m，1H)，8.01(br，1H)，7.78(s，1H)，7.48-7.36(m，2H)，3.65-3.50(m，10H)，2.73-2.65(m，3H)，1.90-1.82(m，10H)。
Example 20
The compound (I-20) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- ((2-pyrimidinyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-20Example 1 the procedure was carried out starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and (2-pyrimidinyl) piperazines. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- ((2-pyrimidinyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-20), white solid. MS (m/z): 489[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.57-8.46(m，4H)，8.01(br，1H)，8.39(m，1H)，7.87(m，1H)，7.49-7.36(m，2H)，6.92(m，1H)，3.57-3.41(m，10H)，2.73-2.69(t，J＝5.6Hz，2H)。
Example 21
The compound (I-21) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (n-propylpiperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-21 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one and n-propylpiperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (n-propylpiperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-21), white solid. MS (m/z): 453[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.57(s，1H)，8.40(m，1H)，8.01-7.89(m，2H)，7.46-7.34(m，2H)，3.48-3.42(m，6H)，2.73-2.57(m，8H)，1.45-1.42(m，2H)，0.93-0.89(t，J＝5.6Hz，3H)。
Example 22
The compound (I-22) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (benzoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-22 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 1- (benzoyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (benzoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-22), white solid. MS (m/z): 515[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.58(s，1H)，8.41(m，1H)，8.03-8.00(m，3H)，7.73-7.65(m，4H)，7.47-7.34(m，2H)，3.63-3.43(m，10H)，2.73-2.70(m，2H)。
Example 23
The compound (I-23) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (2-trifluoromethyl-5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [1, 5-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-23 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 2-trifluoromethyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]A pyrazine. To obtain a final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (2-trifluoromethyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-23), white solid. MS (m/z): 517[ M + H]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.58(s，1H)，8.41(m，1H)，8.01-7.88(m，2H)，7.46-7.39(m，2H)，4.45(s，2H)，4.02-3.97(m，2H)，3.64-3.54(m，4H)，2.72-2.69(m，2H)。
Example 24
The compound (I-24) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (2-methyl-5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [1, 5-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-24 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 2-methyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (2-methyl-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-24), white solid. MS (m/z): 463[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.57(s，1H)，8.40(m，1H)，8.00-7.89(m，2H)，7.49-7.37(m，2H)，4.45(s，2H)，4.03-4.00(m，2H)，3.68-3.49(m，4H)，2.73-2.69(t，J＝5.6Hz，2H)，2.44(s，3H)。
Example 25
The compound (I-25) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [1, 5-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-25 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-25), white solid. MS (m/z): 449[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.59(s，1H)，8.41-8.39(m，1H)，8.01-7.90(m，3H)，7.47-7.36(m，2H)，4.45(s，2H)，4.05-4.01(m，2H)，3.68-3.54(m，4H)，2.70-2.67(m，2H)。
Example 26
The compound (I-26) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (3-hydroxy-5, 6, 7, 8-tetrahydroimidazo [1, 2-a ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
The synthesis of compound I-26 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 3-hydroxy-5, 6, 7, 8-tetrahydroimidazo [1, 2-a ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (3-hydroxy-5, 6, 7, 8-tetrahydroimidazo [1, 2-a ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-26), white solid. MS (m/z): 464[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.54(br，1H)，11.39(br，1H)，8.58(s，1H)，8.40-8.39(m，1H)，8.01-7.92(m，2H)，7.45-7.36(m，2H)，7.01(s，1H)，4.45-4.35(m，4H)，4.05-4.01(m，2H)，3.65-3.55(m，4H)，2.74-2.69(t，J＝5.6Hz，2H)。
Example 27
The compound (I-27) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (2-cyano-5, 6, 7, 8-tetrahydro [1, 2, 4] triazolo [1, 5-A ] pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-27 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 2-cyano-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (2-cyano-5, 6, 7, 8-tetrahydro [1, 2, 4]]Triazole [1, 5-A ]]Pyrazine-7-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-27), white solid. MS (m/z): 474[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.58(s，1H)，8.40(m，1H)，8.01-7.88(m，2H)，7.45-7.37(m，2H)，4.46(s，2H)，4.03-4.01(m，2H)，3.63-3.54(m，4H)，2.71-2.69(m，2H)。
Example 28
The compound (I-28) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (7-fluoro-1, 2, 3, 4-tetrahydropyrrolo [1, 2-a ] pyrazine-2-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-28 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 7-fluoro-1, 2, 3, 4-tetrahydropyrrolo [1, 2-a ]]A pyrazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (7-fluoro-1, 2, 3, 4-tetrahydropyrrolo [1, 2-a ]]Pyrazine-2-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-28), white solid. MS (m/z): 465[ M + H]+。1H NMR(DMSO-d6)：δ：11.36(br，1H)，8.57(s，1H)，8.40(m，1H)，8.01-7.88(m，2H)，7.47-7.36(m，2H)，6.86(s，1H)，5.88(s，1H)，4.48-4.42(m，4H)，3.65-3.54(m，4H)，2.71-2.68(m，2H)。
Example 29
The compound (I-29) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-thienyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-29 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and (2-thienyl) piperazines. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-thienyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-29), white solid. MS (m/z): 493[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.58(s，1H)，8.41(m，1H)，8.12(br，1H)，8.02-7.89(m，3H)，7.53-7.41(m，3H)，6.65-6.63(m，1H)，3.82-3.67(m，10H)，2.72-2.68(t，J＝8.0Hz，2H)。
Example 30
The compound (I-30) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-furyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-30 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and (2-furyl) piperazines. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-furyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-30), white solid. MS (m/z): 477[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.59(s，1H)，8.42(m，1H)，8.11(br，1H)，8.01-7.89(m，3H)，7.52-7.44(m，3H)，6.66-6.65(m，1H)，3.83-3.67(m，10H)，2.70-2.66(t，J＝8.0Hz，2H)。
Example 31
The compound (I-31) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (4-pyridinyloxy) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
The synthesis of compound I-31 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]benzazepin-6-one and 1- (4-pyridinoyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (4-pyridine acyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-31), white solid. MS (m/z): 516[ M + H]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.93(m，1H)，8.58(s，1H)，8.42(m，1H)，8.03-7.98(m，4H)，7.72-7.67(m，3H)，3.63-3.42(m，10H)，2.73-2.70(m，2H)。
Example 32
The compound (I-32) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-thiophenoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-32 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-ones and 1- (2-thiophenoyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-thiophenoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-32), white solid. MS (m/z): 521[ M + H]+。1H NMR(DMSO-d6)：δ：11.39(br，1H)，8.59(s，1H)，8.42-8.38(m，2H)，8.01-7.98(m，3H)，7.71-7.67(m，3H)，3.64-3.47(m，10H)，2.70-2.66(t，J＝8.0Hz，2H)。
Example 33
The compound (I-33) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-furoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-33 by the method of example 1, starting with 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one and 1- (2-furoyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-furoyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-33), white solid. MS (m/z): 505[ M + H]+。1H NMR(DMSO-d6)：δ：11.38(br，1H)，8.59(s，1H)，8.43-8.38(m，2H)，8.04-7.99(m，3H)，7.72-7.67(m，3H)，3.63-3.45(m，10H)，2.71-2.67(t，J＝8.0Hz，2H)。
Example 34
The compound (I-34) 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-thiophenesulfonyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one
Synthesis of Compound I-34 was carried out as in example 1 starting from 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3-carboxyphenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one and 1- (2-thiophenesulfonyl) piperazine. To obtain the final product 8-fluoro-1, 3,4, 5-tetrahydro-2- (4-fluoro-3- (4- (2-thiophenesulfonyl) piperazine-1-carbonyl) phenyl) -6H-pyrrolo [4,3,2-EF][2]Benzazepin-6-one (I-34), white solid. MS (m/z): 557[ M + H ]]+。1H NMR(DMSO-d6)：δ：11.37(br，1H)，8.58(s，1H)，8.42-8.39(m，2H)，8.03-7.99(m，3H)，7.73-7.67(m，3H)，3.62-3.46(m，10H)，2.71-2.67(t，J＝8.0Hz，2H)。
Example 35
Biological assay
PARP-1 Activity assay: PARP-1 activity was determined using the HT Universal chemiluminescent PARP assay kit (Trevigen, Gaithersburg, Md., USA). Assay incorporation of biotin poly (ADP-ribose) into histone catalyzed by PARP-1 after activation of the measured DNA was measured. The experimental procedure was performed according to the instructions provided with the assay kit. That is, in histone-coated wells, PARP-1(0.5 units/well) was incubated with activated DNA and NAD + in reaction buffer for 45 minutes at 25 ℃ in the presence or absence of test article. After incubation, the wells were washed with PBS containing 0.1% Triton X-100 and incubated with Strep-HRP for 60 minutes at 25 ℃. Immediately after addition of PeroxyGlowTM to the wells, chemiluminescence was measured with a VictorX52030 Multilabel Reader (Perkin Elmer). IC calculation Using the Medium-Effect method (Chou, T.C. (2006); Pharmacol. Rev.58 (3): 621-50The value is obtained. IC of the example Compounds50The values are shown in table 2.
PARP-2 Activity assay: PARP-2 activity assays were performed according to the PARP-1 assay.
Cell proliferationAnd (3) cloning analysis: MDA-MB-436 cells were purchased from American Type Culture Collection (USA). Cells were maintained at 37 ℃ and 5% CO2In a humid atmosphere. For proliferation assays, MDA-MB-436 cells were seeded at low density in 96-well plates in RPMI-1640 medium supplemented with 10% FBS and at 37 ℃ in 5% CO2Incubated for 24h in a humid atmosphere. Cells were incubated for a further 7 days at 37 ℃ in fresh medium in the presence or absence of test article. By using
Aqueous phase nonradioactive cell proliferation kit (Promega) cell proliferation was measured by 3- (4, 5-dimethylthiazol-2-yl) -5- (-3-hydroxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazole (MTS) assay. Absorbance at 490nm was determined by Victor X52030 Multilabel Reader (Perkin Elmer) (A490). EC was calculated using the mesogenic method (Chou, T.C. (2006). Pharmacol. Rev.58 (3): 621-Bu 681)50The value is obtained. EC of the Compounds of examples50The values are shown in table 2.
Table 2. test results:
note: a is more than 500nM, B is more than 100nM and more than or equal to 500nM, C is more than or equal to 100nM and more than or equal to 20nM, and D is less than or equal to 20 nM.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610220316.0A CN107286166B (en) | 2016-04-11 | 2016-04-11 | Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610220316.0A CN107286166B (en) | 2016-04-11 | 2016-04-11 | Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107286166A CN107286166A (en) | 2017-10-24 |
| CN107286166B true CN107286166B (en) | 2020-03-31 |
Family
ID=60095512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610220316.0A Active CN107286166B (en) | 2016-04-11 | 2016-04-11 | Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107286166B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020012066A (en) * | 2018-05-14 | 2021-04-28 | Nuvation Bio Inc | ANTICANCER COMPOUNDS TARGETED AT NUCLEAR HORMONE RECEPTORS. |
| WO2020232119A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| JP2024510792A (en) | 2021-03-23 | 2024-03-11 | ニューベイション・バイオ・インコーポレイテッド | Anti-cancer nuclear hormone receptor targeting compound |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342161A (en) * | 1999-01-11 | 2002-03-27 | 阿古龙制药公司 | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| CN104754942A (en) * | 2012-09-05 | 2015-07-01 | 拜尔农作物科学股份公司 | Use of substituted benzodiazepines and benzazepines or their salts as active substances against abiotic stress in plants |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015166398A1 (en) * | 2014-04-30 | 2015-11-05 | Aurigene Discovery Technologies Limited | 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors |
-
2016
- 2016-04-11 CN CN201610220316.0A patent/CN107286166B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342161A (en) * | 1999-01-11 | 2002-03-27 | 阿古龙制药公司 | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| CN104754942A (en) * | 2012-09-05 | 2015-07-01 | 拜尔农作物科学股份公司 | Use of substituted benzodiazepines and benzazepines or their salts as active substances against abiotic stress in plants |
Non-Patent Citations (1)
| Title |
|---|
| Novel Tricyclic Poly(ADP-ribose)Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity:Design,Synthesis,and X-ray Cocrystal Structure;Stacie S.Canan Koch et al.;《J.Med.Chem》;20021015;第45卷(第23期);第4961-4974页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107286166A (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107286174B (en) | Substituted 2,4- (1H,3H) pyrimidinedione as PARP inhibitor and application thereof | |
| CN107629071B (en) | Substituted 2,4- (1H,3H) pyrimidinedione as PARP inhibitor and application thereof | |
| EP2964223B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| CN108570059B (en) | Compound with PRMT5 inhibitory activity and preparation and application thereof | |
| WO2020259432A1 (en) | Kras-g12c inhibitor | |
| KR101877187B1 (en) | Substituted dihydroisoquinolinone compounds | |
| CN106220644B (en) | Fused ring pyrimidine amino derivative, preparation method, intermediate, pharmaceutical composition and application thereof | |
| WO2021129824A1 (en) | New-type k-ras g12c inhibitor | |
| CN107286166B (en) | Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives | |
| WO2001083456A1 (en) | Condensed heteroaryl derivatives | |
| WO2008047831A1 (en) | Jak inhibitor | |
| BRPI0915273B1 (en) | TRICYCLICAL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS AND ITS METHODS OF PREPARATION | |
| CN115515589A (en) | ULK1/2 inhibitors and methods of use thereof | |
| WO2024199108A1 (en) | Compound acting as wrn helicase inhibitor | |
| CN115703761A (en) | Compound as WWP1 inhibitor and application thereof | |
| CN117285485A (en) | Bis-sulfonamide derivative and preparation method and application thereof | |
| WO2004009556A1 (en) | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative | |
| WO2024026423A1 (en) | Substituted quinoline derivatives as pi3k inhibitors | |
| CN109232575B (en) | Pyrrole [1,2-b ] pyridazine compound or pharmaceutically acceptable salt thereof and application thereof | |
| CN117402161A (en) | Sulfoxide imine compound with FGFR inhibition effect, pharmaceutical composition containing sulfoxide imine compound and application of sulfoxide imine compound | |
| CN108484574B (en) | Preparation and Application of Tetrahydroisoquinoline Derivatives | |
| CN117304182A (en) | Compound with pyrimidohexa ring structure, pharmaceutical composition containing same and application of compound | |
| CN110668992A (en) | IDO/HDAC double-target compound and synthetic method and application thereof | |
| CN104860945B (en) | Condense acridine derivatives and pharmaceutical composition, preparation method and application | |
| CN106565599A (en) | 2-aminomethylpyridylnicotinamides and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Shanghai Xunhe Pharmaceutical Technology Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20241218 Granted publication date: 20200331 |
|
| PP01 | Preservation of patent right |